Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer

September 04, 2018
1343705
Cancer, Cancer-Gynecologic
Tashanna Myers, MD
Baystate Medical Center, 759 Chestnut St, Springfield, MA
This phase II trial studies how well olaparib and cediranib maleate work in treating patients with endometrial cancer that has come back (recurrent), does not respond to treatment (refractory), or has spread to other places in the body (metastatic). Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No
Active
Interventional (Clinical Trial), Randomized
2
Laura Sorci
413-794-3188